Enlivex commences phase II study of Allocetra in COVID-19 patients
Category: #health  By Mateen Dalal  Date: 2020-05-09
  • share
  • Twitter
  • Facebook
  • LinkedIn

Enlivex commences phase II study of Allocetra in COVID-19 patients

The world has joined forces to develop a vaccine for COVID-19 and companies across the globe are scrambling for the first breakthrough. Since the coronavirus spreads easily and is already weakening the healthcare systems of most nations, a vaccine seems to be the most important way of putting a pause on the spread of coronavirus disease.

In a bid to develop a vaccine for COVID-19, Enlivex Therapeutics Ltd., a clinical-stage biopharmaceutical company, has reportedly started a phase II human clinical trial of AllocetraTM. This Phase II multi-center investigator-initiated clinical study is anticipated to recruit up to five COVID-19 patients in each participating center. The study will evaluate AllocetraTM together with standard care therapy in COVID-19 patients with lung dysfunction.

According to sources, the company will evaluate cytokine, tolerability, and safety of the drug with a change in the PaO2/FiO2 ratio number. The severity of adverse as well as serious adverse events will serve as the co-primary study endpoints of the clinical trial.

The COVID-19 clinical study is anticipated to run independently of the company’s presently planned Phase IIb clinical study of AllocetraTM for treating sepsis. This clinical trial will be a randomized, controlled clinical study that would commence in the Q4 2020.

Speaking on the clinical trial Prof. Dror Mevorach, M.D., Chief Medical and Scientific Officer at Enlivex said that this newly commenced clinical trial represented a unique opportunity for the company to help the world for combating COVID-19 pandemic.

Mr. Mevorach added that the company is excited to learn if initial positive results in sepsis patients treated with AllocetraTM translate to COVID-19 patients with the same underlying pathologies. Moreover, the scientific insights that could be gained from this clinical trial may help in developing other COVID-19 therapies and AllocetraTM-based therapies for diseases in addition to sepsis, stated Mevorach.

Source Credit - https://www.enlivex.com/investor-relations/#latest-news

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

NHS requests urgent donations of blood plasma from COVID-19 survivors
NHS requests urgent donations of blood plasma from COVID-19 survivors
By Mateen Dalal

According to reliable sources, United Kingdom National Health Service (NHS) has filed an appeal to the individuals recuperated from novel coronavirus to donate blood plasma. The organization apparently intends to treat the people who get infected dur...

OSE Immunotherapeutics receives $228,000 to develop COVID-19 vaccine
OSE Immunotherapeutics receives $228,000 to develop COVID-19 vaccine
By Mateen Dalal

The novel coronavirus outbreak has turned out to be one of the worst disasters the world has witnessed in recent times. At times like this, pharmaceutical companies worldwide have been putting their best foot forward to find the vaccine for COVID-19....

Singapore’s ESR and Sabana REIT propose merger amid pandemic
Singapore’s ESR and Sabana REIT propose merger amid pandemic
By Mateen Dalal

Although the economic impact of the ongoing COVID-19 has significantly impacted prospects for Singapores REITs (Real Estate Investment Trusts), it seems that some resilient spots in the real estate sector will remain where they were. In the latest st...